Über uns

Our Collaboration with Biopharma Clients

InSymbiosis has developed a flexible approach to working with our biopharma clients. Since the needs of our clients differ, our model is adaptive and customizable. In general we work with our clients under variations of one of two model types:

Model 1: Functional Outsourcing model

In this model, the client retains full responsibility for the development of their drug asset. The client outsources “parts” of the program (for example, their toxicology program or clinical study etc) to InSymbiosis and we deliver upon the mandate via leveraging our virtual CRO (vCRO) model. Under this approach, InSymbiosis behaves purely as a CRO but with the obvious advantages of:

· project management and oversight

· access to our multidisciplinary drug development team

· “one-stop-shopping” experience for all outsourcing needs

· assurance of quality and scientific integrity

· significant cost savings as delivered by our innovative model

Model 2: Fully Managed Drug Development (FMDD) model

In the FMDD model, the client often externalizes the entire drug development program to InSymbiosis and we assume a greater level of responsibility for the overall program that can include:

· the complete management of all aspects of a drug development program up to and including assembly of all regulatory documentation

or

· a jointly driven program where for example, the client handles regulatory strategy/activities and the overall scientific direction and InSymbiosis handles all other aspects of the program.

Like Model 1, InSymbiosis leverages it’s innovative financial approach to ensure that the clients outsourcing budget is significantly reduced. The FMDD further lends itself as an ideal platform for risk shared approaches.